# A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Source: https://onco.cc/trials/nct05309421/  
OnCo record `nct05309421` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab in melanoma, run by Evaxion Biotech A/S, active and no longer recruiting.

## Summary

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma is a phase 2 interventional study registered as NCT05309421 by Evaxion Biotech A/S, with 17 participants enrolled, started 2022-09-19 and due to reach its primary completion in 2025-09-30. Interventions recorded: EVX-01, Pembrolizumab 25 MG/ML. Conditions listed: Melanoma Stage IV, Unresectable Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05309421
- Phase: 2
- Setting: An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma
- Sponsor: Evaxion Biotech A/S
- Enrolled: 17

## Sources

- ClinicalTrials.gov NCT05309421: https://clinicaltrials.gov/study/NCT05309421

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Evaxion](https://onco.cc/companies/evaxion/)

---
JSON: https://onco.cc/api/v1/entities/nct05309421.json